Skip to main content
Log in

High and prolonged pulmonary tissue concentrations of azithromycin following a single oral dose

  • Pharmacokinetics
  • Published:
European Journal of Clinical Microbiology and Infectious Diseases Aims and scope Submit manuscript

Abstract

Antibiotic concentrations in pulmonary tissue samples and plasma were studied in this open investigation. Twenty-nine patients scheduled for elective pulmonary surgery received a single oral dose of 500 mg azithromycin 24, 72, 96 or 120 h prior to the operation; two patients received 250 mg b.i.d. Blood samples were taken before and at the time of resection, and tissue was obtained during surgery. Plasma and tissue concentrations of azithromycin were measured by high performance liquid chromatography (HPLC) and a microbiological bioassay. Only one patient had a detectable plasma concentration of azithromycin (0.13 µg/ml), measured 24 h post-dose by HPLC. However, high and sustained levels were found in lung tissue: mean concentrations measured by HPLC were 3.10 µg/g (SD ± 2.17), 2.55 µg/g (SD ± 1.36), 3.94 µg/g (SD ± 2.40) and 3.13 µg/g (SD ± 0.50) at 24, 72, 96 and 120 h, respectively. Bioassay results were similar to those for the HPLC assay. In summary, azithromycin levels in pulmonary tissue remained close to 3 µg/g for up to 5 days after a single oral 500 mg dose, in contrast to plasma levels which were much lower. The lung concentrations found are inhibitory for many sensitive respiratory pathogens and short-course azithromycin therapy is therefore a possibility.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Bright GM, Nagel AA, Bordner J, Desai KA, Dibrino JN, Nowakowska J, Vincent L, Watrous RM, Sciavolino FC: Synthesis, in vitro and in vivo activity of novel 9-deoxo-9a-aza-9a homoerythromycin A derivative; a new class of macrolide antibiotics, the azalides. Journal of Antibiotics 1988, 41: 1029–1047.

    PubMed  Google Scholar 

  2. Hardy DJ, Hensey DM, Beyer JM, Vojtko C, McDonald EJ, Fernandes PB: Comparative in vitro activities of new 14-, 15- and 16-membered macrolides. Antimicrobial Agents and Chemotherapy 1988, 32: 1710–1719.

    PubMed  Google Scholar 

  3. Lassus A: Comparative study of azithromycin in skin and soft tissue infections and sexually transmitted infection byNeisseria andChlamydia species. Journal of Antimicrobial Chemotherapy 1990, 25, Supplement A: 115–121.

    Google Scholar 

  4. Schönwald S, Gunjaca M, Kolacny-Babic L, Car V, Gosev M: Comparison of azithromycin and erythromycin in the treatment of atypical pneumonias. Journal of Antimicrobial Chemotherapy 1990, 25, Supplement A: 123–126.

    PubMed  Google Scholar 

  5. Foulds G, Shepard RM, Johnson RB: The pharmacokinetics of azithromycin in human serum and tissues. Journal of Antimicrobial Chemotherapy 1990, 25, Supplement A: 73–82.

    Google Scholar 

  6. Baldwin DR, Wise R, Andrews JM, Ashby D, Honeybourne D: Azithromycin concentrations at the sites of pulmonary infection. European Respiratory Journal 1990, 3: 886–890.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Morris, D.L., De Souza, A., Jones, J.A. et al. High and prolonged pulmonary tissue concentrations of azithromycin following a single oral dose. Eur. J. Clin. Microbiol. Infect. Dis. 10, 859–861 (1991). https://doi.org/10.1007/BF01975842

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01975842

Keywords

Navigation